Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 1

Status

Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Breast 1

Conditions

Breast Neoplasms 16Colorectal Neoplasms 4Brain Neoplasms 4Neoplasms 3Meningeal Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Colonic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Pathologic Complete Response 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Carcinomatosis 1Hemangiosarcoma 1HER2-positive Gastric Cancer 1HER2-positive Breast Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Temozolomide 73Bevacizumab 57Radiotherapy 40Radiosurgery 28Carboplatin 23Nivolumab 17Etoposide 17Cisplatin 17pembrolizumab 16Irinotecan 16Ipilimumab 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Cyclophosphamide 14Carmustine 14Pemetrexed 13Topotecan 10Surgical Procedures, Operative 10Capecitabine 10Lapatinib 9Filgrastim 9Trastuzumab 8Thalidomide 8Sunitinib 8Paclitaxel 8Lomustine 8Aminolevulinic Acid 8encorafenib 7binimetinib 7Vincristine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Brain Neoplasms × tucatinib × Clear all
NCT05323955 2026-03-17

BRIDGET

Duke University

Phase 2 Active not recruiting
48 enrolled
CNS

Brain Neoplasms

NCT05673928 2026-01-21

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT02614794 2023-08-14

HER2CLIMB

Seagen Inc.

Phase 2 Completed
612 enrolled 30 charts 1 FDA
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
120 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡